Overview

Recombinant Vaccines Market is predicted to value over CAGR of over 11.3% during the forecast period 2022 to 2028.

Recombinant vaccines are developed using genetic engineering or recombinant DNA technology for preventing chronic diseases. These vaccines activate the T-cell and antigen trigger, thereby generating an immune response that is cell mediated against an immunogen. Rise in the number of regulatory approvals, increased advancements in device technologies, growing incidences of infectious diseases are some of the factors contributing to the recombinant vaccines market growth. Moreover, rising awareness amongst general population regarding the prevalence of chronic infectious diseases, favourable policies for reimbursements, rising disposable income are some other markets propelling the market augmentation. However, risks related to live vaccines that are attenuated, high vaccine costs, strict regulations shall possibly restrain the market growth.
Many companies have received regulatory clearances in recent years has positively impacted the market growth. Merck, in December 2019, were awarded an approval from the US FDA for an Ebola vaccine named ERVEBO while in October 2017, GlaxoSmithKline received an FDA approval for their herpes zoster vaccine SHINGRIX. Such regulatory approvals for crucial drugs shall boost the proliferation of the market. These approvals are important as many people are losing their lives to these fatal diseases. According to the WHO report,2017, over 2 million deaths can be prevented every year which has paved way for newer vaccines.

Market Segmentation:

By Type
•   Subunit
•   Live Attenuated
By Route of Administration
•   Parenteral
•   Oral
By Disease Indication
•   Human Papillomavirus
•   Hepatitis B
•   Rotavirus
•   Herpes Zoster
•   Meningococcal B
•   Others
By Distribution Channel
•   Hospitals & Retail Pharmacies
•   Government Suppliers
•   Others
By Region
•   North America
•   Europe
•   Asia-Pacific
•   Latin America
•   Middle East and Africa

The market is fragmented into type, route of administration, disease indication, distribution channel and region. The type segment is categorised into subunit and live attenuated while the route of administration segment is bifurcated into parenteral and oral. The disease indication segment is divided into human papillomavirus, hepatitis B, rotavirus, herpes zoster, meningococcal B and others. The hepatitis B segment is anticipated to hold the largest recombinant vaccines market share owing to rising prevalence of hepatitis B in developing countries where the scope of drug development is wide with key players expanding their business operations in such countries. The distribution channel segment is classified into hospital and retail pharmacies, government suppliers and others. The hospital and retail pharmacies segment is predicted to lead the market during the forecasted timeframe owing to advancements in hospital infrastructure, rise in the number of multispecialty hospitals in emerging economies and availability of skilled labour in hospital settings.

Regional Analysis:

The North America region is expected to subjugate the market during the forecast period owing to a rising prevalence of cancer in the region. As per the National Cancer Institute, over 16 lakh new cancer cases were recorded and over 595,000 deaths were registered in 2016. Such high incidence rate of cancer shall boost the proliferation of the market in the region.

Competitive Landscape:

Some of the important market players are Merck & Co. Inc., Novartis AG, Protein Science Corporation, GlaxoSmithKline Plc., Green Cross Corporation, Bayer AG, Sanofi SA, Pfizer Inc., Bharat Biotech.

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key market trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the global recombinant vaccines market by type, by route of administration, by disease indication, by distribution channel and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
• To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•   We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•   The customization Mobility Care offered are free of charge with purchase of any license of the report
•   You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com